A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus
Authors:
- 1 May 2019
- journal article
- review article
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 13 (3) , 2001-2008
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteersInt. Journal of Clinical Pharmacology and Therapeutics, 2013
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male VolunteersClinical Therapeutics, 2013
- Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy VolunteersAdvances in Therapy, 2012
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism, 2011
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Sodium–glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drugDiabetes, Obesity and Metabolism, 2008
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.Journal of Clinical Investigation, 1987